Xiao et al. found that ELF1/CASC2/miR-18a axis-mediated IRF2 expression is significantly related to the proliferation, migration, and invasion of cisplatin-resistant NSCLC, and they believe that this regulatory axis may be a new therapeutic target for NSCLC [56]. This evidence concerns the gene CASC2 and non-small cell lung carcinoma.